Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
about
Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients.Optimal management of skin cancer in immunosuppressed patients.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Recurrent in situ melanoma successfully treated with ingenol mebutate.Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice
P2860
Q35767304-9F2DCD5C-F4DD-4762-ADC0-8D77CDBD3F5DQ37741996-25928622-2946-426E-9144-86A08AC538B2Q38228585-2D711CA5-4995-4613-A9A6-99DD8F491DF3Q38546598-96341D40-35B2-4C44-B213-A17A47493D65Q40946140-F1C7AB64-5754-452D-8A43-E92E05CA6DD8Q47096038-2EA8EDD7-2BD2-418A-9D48-CB69916BD077Q57484131-6920DCB7-8420-488A-8AFC-C5ECA00D8A4E
P2860
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
@en
type
label
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
@en
prefLabel
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
@en
P2860
P1433
P1476
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
@en
P2860
P304
P356
10.2165/11470090-000000000-00000
P577
2012-12-01T00:00:00Z
P6179
1029537456